A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal.

@article{Mastri2018ATP,
  title={A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal.},
  author={Michalis Mastri and Amanda Tracz and Christina R. Lee and Melissa Dolan and Kristopher Attwood and James G. Christensen and Song Liu and John M. L. Ebos},
  journal={Cell reports},
  year={2018},
  volume={25 13},
  pages={
          3706-3720.e8
        }
}
VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) approved to treat multiple cancer types can promote metastatic disease in certain limited preclinical settings. Here, we show that stopping VEGFR TKI treatment after resistance can lead to rebound tumor growth that is driven by cellular changes resembling senescence-associated secretory phenotypes (SASPs) known to promote cancer progression. A SASP-mimicking antiangiogenic therapy-induced secretome (ATIS) was found to persist during short… Expand
11 Citations
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
TLDR
Results suggest that the diverse and often inconsistent compensatory signaling mechanisms found to contribute to TKI resistance may paradoxically improve the tumor-inhibiting effects of broad-spectrum TKIs such as sitravatinib that are able to block multiple signaling pathways. Expand
New Insights into Therapy-Induced Progression of Cancer
TLDR
This review summarizes mechanisms of acquired resistance, such as secondary genetic alterations, impaired function of drug transporters, and autophagy, and describes less obvious molecular aspects of therapy resistance in cancers, including epithelial-to-mesenchymal transition, cell cycle alterations, and the role of intercellular communication. Expand
Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence.
TLDR
It is demonstrated that sustained inhibition of PARP-1 activity during radiation treatment significantly delayed recurrence in vitro as well in vivo in orthotopic GBM mouse models with a significant increase in overall survival of mice. Expand
Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer.
TLDR
This review will focus on recent evidence regarding therapy-induced senescence (TIS) from anti-cancer agents, including chemotherapy, radiation, immunotherapy, and targeted therapies, and how each therapy can trigger the SASP, which in turn influences treatment efficacy. Expand
Biological functions of therapy-induced senescence in cancer.
TLDR
Cell-aut autonomous and non-cell-autonomous mechanisms that senescent cells activate in response to chemotherapy and radiation leading to tumor suppression and tumor promotion are described and the current state of knowledge on the stimuli that affect the activation of these opposing mechanisms are presented. Expand
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence.
TLDR
This work outlines how the tumour cell secretome (TCS) can protect cancer cells from chemotherapy-induced cell death and highlights recent evidence describing how therapy-induced TCS can impact cancer stem cell expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity. Expand
Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells
TLDR
It is shown that prolonged PD-L1 inhibition can ‘rewire’ existing intracellular IFN:PD-L 1 signaling crosstalk to drive secretory programs that help protect tumors from immune cell attack and represent a targetable vulnerability to overcome acquired resistance in patients. Expand
Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma
TLDR
It is established that inhibiting ABCB-1 with elacridar, in addition to sunitinib, has a positive impact on reverting sunit inib-resistance development in in vitro, ex vivo and in vivo models. Expand
Adaptive response of resistant cancer cells to chemotherapy
TLDR
The mechanistic studies investigating the three major components of the adaptive response, autophagy, endoplasmic reticulum (ER) stress signaling, and senescence, in response to cancer chemotherapy are summarized. Expand
Tumor growth fueled by spurious senescence phenotypes
TLDR
It is found that antiangiogenic treatment resistance can lead to a transient hijacking of the senescence-controlled secretory machinery that, when therapeutically targeted during treatment cessation, can blunt rebound tumor growth. Expand
...
1
2
...

References

SHOWING 1-10 OF 81 REFERENCES
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
TLDR
FAK may be a unique target in situations in which antiangiogenic agents are withdrawn, and dual targeting of FAK and VEGF could have therapeutic implications for ovarian cancer management. Expand
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
TLDR
The results suggest that observed sunitinib-induced molecular plasma changes represent a systemic tumor-independent response to therapy and may correlate with the most efficacious antitumor doses, potentially having utility for defining the optimal biologic dose range for this drug class but not as predictive markers of tumor response or clinical benefit. Expand
Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
TLDR
These are the first studies to assess and compare “off-target” host secretory effects of VEGF and PD-1 pathway inhibition that occur independent of tumor stage or tumor response to therapy, and show that host TIS signatures differ between drug target, drug class, and dose. Expand
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
TLDR
Evidence for tumor adaptation to vascular endothelial growth factor blockade through a metabolic shift toward carbohydrate and lipid metabolism in tumors is provided and key molecules involved in lipid metabolism as putative therapeutic targets are identified. Expand
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
Summary Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, andExpand
A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.
TLDR
An acute chemotherapy-induced secretory response that is self-limiting in vitro and in vivo despite the induction of cellular senescence is detailed and a mechanism by which damage-associated paracrine secretory responses are restrained to preserve tissue homeostasis and prevent chronic inflammation is described. Expand
The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.
TLDR
The challenges of studying inhibitors of the tumor microenvironment in the preclinical setting are highlighted and the need for improved methodology to assist in qualifying (and quantifying) treatment failure to identify mechanisms that will help predict alternative strategies in patients is highlighted. Expand
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
TLDR
Key challenges facing the preclinical and clinical development of antiangiogenic agents are discussed, including potential differences in drug efficacies when treating primary tumors or various stages of metastatic disease. Expand
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
TLDR
Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development. Expand
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
TLDR
Using mouse models of breast, kidney, and melanoma metastasis, it is demonstrated that primary tumor responses to neoadjuvant VEGFR TKI treatment do not consistently correlate with improved post‐surgical survival, with survival worsened in certain settings. Expand
...
1
2
3
4
5
...